La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
China Resources Pharmaceutical Group Crescita futura
Future criteri di controllo 2/6
China Resources Pharmaceutical Group prevede che gli utili e i ricavi cresceranno rispettivamente di 7.4% e 8.4% all'anno. Si prevede che l'EPS crescerà di 7.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 8.5% in 3 anni.
Informazioni chiave
7.4%
Tasso di crescita degli utili
7.1%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 11.2% |
| Tasso di crescita dei ricavi | 8.4% |
| Rendimento futuro del capitale proprio | 8.5% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 18 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 327,255 | 5,271 | 9,353 | 13,179 | 7 |
| 12/31/2025 | 297,310 | 4,870 | 6,275 | 10,390 | 10 |
| 12/31/2024 | 267,736 | 4,327 | 4,433 | 12,346 | 9 |
| 12/31/2023 | 244,704 | 3,854 | 12,550 | 15,550 | N/A |
| 9/30/2023 | 239,207 | 3,722 | 9,931 | 12,658 | N/A |
| 6/30/2023 | 247,532 | 3,852 | 7,840 | 10,729 | N/A |
| 3/31/2023 | 228,091 | 3,634 | 7,785 | 10,594 | N/A |
| 12/31/2022 | 218,183 | 3,500 | 8,239 | 10,821 | N/A |
| 9/30/2022 | 221,487 | 3,724 | 7,431 | 10,371 | N/A |
| 6/30/2022 | 211,788 | 3,719 | 6,240 | 9,347 | N/A |
| 3/31/2022 | 196,226 | 3,288 | 6,935 | 9,628 | N/A |
| 12/31/2021 | 193,021 | 3,072 | 8,009 | 10,468 | N/A |
| 9/30/2021 | 191,495 | 2,869 | 5,958 | 8,155 | N/A |
| 6/30/2021 | 187,554 | 2,626 | 3,792 | 5,694 | N/A |
| 3/31/2021 | 179,512 | 2,720 | 4,521 | 6,344 | N/A |
| 12/31/2020 | 168,762 | 2,776 | 5,194 | 6,910 | N/A |
| 9/30/2020 | 171,873 | 2,683 | 6,986 | 8,696 | N/A |
| 6/30/2020 | 174,956 | 2,578 | 8,914 | 10,616 | N/A |
| 3/31/2020 | 181,054 | 2,793 | 7,272 | 9,038 | N/A |
| 12/31/2019 | 182,690 | 2,937 | 5,488 | 7,274 | N/A |
| 9/30/2019 | 183,417 | 3,670 | 5,658 | 7,406 | N/A |
| 6/30/2019 | 173,938 | 4,187 | 5,510 | 7,124 | N/A |
| 3/31/2019 | 165,679 | 3,737 | 5,370 | 6,990 | N/A |
| 12/31/2018 | 166,626 | 3,494 | 5,528 | 7,244 | N/A |
| 9/30/2018 | 163,734 | 3,466 | 4,984 | 6,419 | N/A |
| 6/30/2018 | 154,852 | 3,309 | 4,276 | 5,387 | N/A |
| 3/31/2018 | 142,296 | 2,959 | 3,266 | 4,493 | N/A |
| 12/31/2017 | 143,688 | 2,901 | 2,586 | 4,045 | N/A |
| 9/30/2017 | 143,252 | 2,759 | N/A | 1,486 | N/A |
| 6/30/2017 | 142,276 | 2,602 | N/A | -1,189 | N/A |
| 3/31/2017 | 142,003 | 2,577 | N/A | 1,219 | N/A |
| 12/31/2016 | 140,316 | 2,526 | N/A | 3,689 | N/A |
| 9/30/2016 | 132,253 | 2,161 | N/A | 4,391 | N/A |
| 6/30/2016 | 129,313 | 1,889 | N/A | 5,222 | N/A |
| 3/31/2016 | 123,770 | 2,103 | N/A | 5,027 | N/A |
| 12/31/2015 | 122,785 | 2,388 | N/A | 5,017 | N/A |
| 12/31/2014 | 108,575 | 2,116 | N/A | 3,349 | N/A |
| 12/31/2013 | 91,313 | 2,061 | N/A | 3,203 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 3320 ( 7.4% all'anno) è superiore al tasso di risparmio ( 2.3% ).
Guadagni vs Mercato: Si prevede che gli utili di 3320 ( 7.4% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 3320 cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di 3320 ( 8.4% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.4% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 3320 ( 8.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 3320 sarà basso tra 3 anni ( 8.5 %).